1-1 of 1
Authors: Yingsi Yang
Journal Article
A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second‐Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma Free
The Oncologist, Volume 22, Issue 3, March 2017, Pages 243–e23, https://doi.org/10.1634/theoncologist.2016-0479
Published: 28 February 2017
